Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Core Viewpoint - Novavax's stock has significantly outperformed the market, returning +104.6% over the past month compared to the S&P 500's +3.3% [1] Earnings Estimates Revisions - The consensus earnings estimate for Novavax is $0.37 for the current fiscal year, reflecting a year-over-year increase of +106.8% and a change of +144.5% over the last 30 days [2] - For the current quarter, Novavax is expected to report earnings of $1.13 per share, indicating a +94.8% change from the same quarter last year, with the consensus estimate changing by +241.6% in the last 30 days [11] - The consensus earnings estimate for the next fiscal year is $0.42, showing a +15.6% change year-over-year, but has seen a drastic change of -840% over the past month [12] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $429.83 million, indicating a year-over-year change of +1.3% [15] - For the current fiscal year, the sales estimate is $999.14 million, reflecting a +1.6% change, while the next fiscal year's estimate is $553.03 million, indicating a -44.7% change [15] - Last reported revenues were $93.86 million, representing a +16% year-over-year change, with an EPS of -$1.05 compared to -$3.41 a year ago [16] Valuation - Novavax is graded D in terms of valuation, indicating it is trading at a premium compared to its peers [8] - The Zacks Value Style Score system helps assess whether Novavax is overvalued, rightly valued, or temporarily undervalued [18] - The Zacks Rank for Novavax is 3 (Hold), suggesting it may perform in line with the broader market in the near term [3][19] Performance History - Over the last four quarters, Novavax has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [20]